A Phase 3 study of SSGJ-707 vs Pembrolizumab in advanced NSCLC
Recruiting Phase 3 NCT06980272
Study Description
Evaluating the efficacy and safety of a new drug (SSGJ-707) compared to Pembrolizumab in patients with advanced non-small cell lung cancer
Study Details
- Registry ID:
- NCT06980272
- Conditions:
- Advanced Non-Small Cell Lung Cancer
- Phase:
- Phase 3
- Target Enrollment:
- 420 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
The Shanghai East Hospital
Shanghai, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.